

Dr. rer. pol. Carl Rudolf Blankart	Address (business)	Address (private)	Phone
*27.04.1980 in Munich ORCID: 0000-0001-6719-0038 Scopus Author ID: 36678751800 ResearcherID: Q-7843-2018	KPM/sitem-insel University of Bern Freiburgstr. 3 3010 Bern/Switzerland	Thunstr. 99 3074 Muri/Switzerland	T +41 31 666 44 30

Professional Experience

Since 02/17	Professor of Regulatory Affairs <i>KPM Center for Public Management, University of Bern</i> <i>Associate Member of the Executive Board</i>	Bern (CH)
Since 02/17	Director Promoting Services <i>Swiss Institute for Translational and Entrepreneurial Medicine (sitem-insel)</i> <i>Member of the Executive Board</i>	Bern (CH)
12/12-01/17	Assistant Professor of Technology and Quality Management in Healthcare <i>Hamburg Center for Health Economics, Universität Hamburg</i> <i>Core Member of the Hamburg Center for Health Economics</i>	Hamburg (DE)
09/15-08/16	The Commonwealth Fund Harkness/B. Braun Stiftung Fellow in Health Care Policy and Practice <i>Brown University School of Public Health</i>	Providence, RI (USA)
10/10-08/12	Researcher and Postdoc <i>Hamburg Center for Health Economics, Universität Hamburg</i>	Hamburg (DE)
05/09-09/10	Researcher <i>Institute of Health Economics and Health Care Management, Helmholtz Zentrum München</i>	Munich (DE)
08/06-03/09	Management consultant <i>CTcon GmbH</i>	Duesseldorf (DE)
12/05-05/06	Research student <i>Greater Manchester Strategic Health Authority, National Health Service (NHS)</i>	Manchester (UK)

Education

09/15-08/16	Research fellow <i>Brown University School of Public Health</i>	Providence, RI (USA)
09/12-11/12	Research fellow at the Centre for Health Policy <i>Imperial College London</i>	London (UK)
10/10-05/12	PhD student at the Institute of Health Care Management <i>Universität Hamburg</i> Graduation in 2012 with distinction “summa cum laude” Supervisor: Prof. Dr. Jonas Schreyögg	Hamburg (DE)
05/09-09/10	Doctorate (PhD) student at the Institute of Health Services Management <i>Ludwig-Maximilians-Universität</i>	Munich (DE)
10/99-06/06	Industrial engineering and management studies (Wirtschaftsingenieurwesen) <i>Technische Universität Berlin</i> Degree: Dipl.-Ing. (Master of Engineering)	Berlin (DE)

Projects granted (selection)

10/21-9/26	IMI Joint Undertaking 2: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies: Screen4Care <i>Principal Investigator for UBERN, Work Package Leader (Coordinator: University of Ferrara)</i>
1/18-12/20	European Commission’s Horizon2020 Programme: Pushing the boundaries of Cost and Outcome analysis of Medical Technologies: COMED (grant no. 779306) <i>Principal Investigator for UBERN, Work Package Leader (Coordinator: Bocconi University)</i>
1/2018-12/2021	International Collaborative on Costs, Outcomes and Needs in Care with The Commonwealth Fund (USA) and The Health Foundation (UK) <i>Co-Investigator</i>
10/17-9/20	Bonny Stiftung für die Freiheit: Multidimensional estimation of regulatory effort and identification of optimization needs (MARANO) <i>Principal Investigator</i>
2/15-9/15	German Federal Ministry of Health: International Country Comparison on the Influence of Reimbursement Systems on the Treatment of Diabetes Patients <i>Principal Investigator</i>
7/14-12/14	The Commonwealth Fund: Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer <i>Principal Investigator</i>

Dr. rer. pol. Carl Rudolf Blankart

1/14-12/15	Industry sponsored project: Private Physician Billing in Germany: The Influence of Institutional Path Dependency on the Design of the Billing System <i>Co-Investigator</i>
1/13-12/15	European Commission's 7th Framework Programme: Methods of Health Technology Assessment for Medical Devices: MedtecHTA (grant no. 305694) <i>Co-Investigator (Coordinator: Bocconi University)</i>
7/12-6/15	Industry sponsored project: Quantification of Effects of Telemedical Care on Expenditure and Quality of Care <i>Co-Investigator</i>

Supervision of junior researchers at graduate and postgraduate level

Supervision of PhD students

- Jean Pierre Uwitonze, M.Sc. (since 2022)
Sandra Gillner, M.Sc. (since 2021)
Lize Duminy, M.Sc. (since 2019)
Kosta Shatrov, M.Sc. (since 2017, graduated with distinction 2022)
Dr. rer. oec. Maximilian Hatz (2013-16, graduated with distinction 2016)
Dr. rer. oec. Yauheniya Varabyova (2013-16, graduated with distinction 2016)

Co-Supervision of PhD students

- Angela Meggiolaro (since 2017)
Dr. rer. oec. Lukas Kwietniewski (graduated 2016)
Ricarda Milstein (graduated 2020)

Mentoring of post-doctoral researcher

- Rowan Iskandar, PhD (9/2019-8/2020)

Teaching Activities

Lectures

- Organization of Health Care Systems (3 ECTS, every 2nd semester)
Health Care Regulation (3 ECTS, every 2nd semester)
Introduction into Health Care Management (9 ECTS, offered at U Hamburg)
Health Insurance Management (6 ECTS, offered at U Hamburg)

Seminars

- Health Care Regulation (6 ECTS, every 2nd semester)
Organization of Health Care Systems (6 ECTS, every 2nd semester)

Board Memberships/Editorial Activities

- Round Table Antibiotics (President)
Swiss Association for the Promotion of Self-Management (President)
International Collaborative on Costs, Outcomes and Needs in Care (Founding member)
Health Policy (Associate Editor)
Swiss Network for Digital Medical Regulation (Member)

Memberships in Scientific Societies

- Gesellschaft für Gesundheitsökonomie (dggö) | Deutsche Gesellschaft für Regulatory Affairs (dgra) | Deutscher Hochschulverband (DHV) | European Health Economics Association (EUHEA) | International Health Economics Association (iHEA) | Swiss Economists Abroad (SEA) | Verband der Hochschullehrer für Betriebswirtschaft (VHB)

Organization of Conferences

- 1st Swiss Translational Medicine Conference, 2022
First Swiss conference on Translational Medicine with a focus on medical devices
MDR Support Panel (2018-2020)
Quarterly event to support SMEs in preparing for the challenges of the new Medical Device Regulation
Swiss Governance Forum, 2018
Conference for political decision makers, practitioners, academics and society on the challenges of digital health
Chronic Care Management Days, 2019
An International Look at Health Care Transformation

Awards and Fellowships

- 2022 Fellow of SCIANA – The health leaders network.
2022 Egon Jonsson Award of Health Technology Assessment international (HTAi)
2017 Best Paper Proceedings at the Academy of Management in Atlanta, GA
2015 Harkness Fellowship in Health Care Policy and Practice, Commonwealth Fund, New York, USA and B. Braun Stiftung, Melsungen

Publications in International Peer-Reviewed Scientific Journals	
Quentin W, Achstetter K, Barros PP, Blankart CR , Fattore G, Jeurissen P, Kwon S, Laba T, Or Z, Papanicolas I, Polin K. Shuftana N, Sutherland J, Vogt V, Vrangbaek K, Wendt C. The best evidence for better policies. <i>Health Policy</i> . 2023 Jan 14.	
Shatrov K, Blankart CR . After the four-year transition period: Is the European Union's Medical Device Regulation of 2017 likely to achieve its main goals?. <i>Health Policy</i> . 2022 Dec 1;126(12):1233-40.	
Lorenzoni L, Marino A, Or Z, Blankart CR , Shatrov K, Wodchis W, Janlov N, Figueroa JF, Bowden N, Bernal-Delgado E, Papanicolas I. Why the US spends more treating high-need high-cost patients: a comparative study of pricing and utilization of care in six high-income countries. <i>Health Policy</i> . 2022 Dec 10.	
Meggioraro A, Blankart CR , Stargardt T, Schreyögg J. An econometric approach to aggregating multiple cardiovascular outcomes in German hospitals. <i>The European Journal of Health Economics</i> . 2022 Sep 16:1-8.	
Iskandar R, Federici C, Berns C, Blankart CR . An approach to quantify parameter uncertainty in early assessment of novel health technologies. <i>Health economics</i> . 2022 May 17.	
Milstein R, Shatrov K, Schmutz LM, Blankart CR . How to pay primary care physicians for SARS-CoV-2 vaccinations: An analysis of 43 EU and OECD countries. <i>Health Policy</i> . 2022 Mar 20.	
Drummond M, Federici C, Reckers-Droog V, Torbica A, Blankart CR , Ciani O, Kaló Z, Kovács S, Brouwer W. Coverage with evidence development for medical devices in Europe: Can practice meet theory?. <i>Health economics</i> . 2022 Feb 26.	
Figueroa JF, Horneffer KE, Riley K, Abiona O, Arvin M, Atsma F, Bernal-Delgado E, Blankart CR , Bowden N, Deeny S, Estupiñán-Romero F, Gauld R, Hansen TM, Haywood P, Janlov N, Knight H, Lorenzoni L, Marino A, Or Z, Pellet L, Orlander D, Penneau A, Schoenfeld AJ, Shatrov K, Skudal KE, Stafford M, van de Galien O, van Gool K, Wodchis WP, Tanke M, Jha AK, Papanicolas I. A methodology for identifying high-need, high-cost patient personas for international comparisons. <i>Health Serv Res</i> 2021;56(S3):1302–16. https://doi.org/10.1111/1475-6773.13890 .	
Duminy L, Sivapragasam NR, Matchar DB, Visaria A, Ansah JP, Blankart CR , Schoenenberger L. Validation and application of a needs-based segmentation tool for cross-country comparisons. <i>Health Serv Res</i> 2021;56(S3):1394–404. https://doi.org/10.1111/1475-6773.13873 .	
Blankart CR , van Gool K, Papanicolas I, Bernal-Delgado E, Bowden N, Estupiñán-Romero F, Gauld R, Knight H, Abiona O, Riley K, Schoenfeld AJ, Shatrov K, Wodchis WP, Figueroa JF, ICCONIC Collaboration. International comparison of spending and utilization at the end of life for hip fracture patients. <i>Health Serv Res</i> 2021;56(S3):1370–82. https://doi.org/10.1111/1475-6773.13734 .	
Or Z, Shatrov K, Penneau A, Wodchis W, Abiona O, Blankart CR , Bowden N, Bernal-Delgado E, Knight H, Lorenzoni L, Marino A, Papanicolas I, Riley K, Pellet L, Estupiñán-Romero F, van Gool K, Figueroa JF. Within and across country variations in treatment of patients with heart failure and diabetes. <i>Health Serv Res</i> 2021;56(S3):1358–69. https://doi.org/10.1111/1475-6773.13854 .	
Papanicolas I, Figueroa JF, Schoenfeld AJ, Riley K, Abiona O, Arvin M, Atsma F, Bernal-Delgado E, Bowden N, Blankart CR , Deeny S, Estupiñán-Romero F, Gauld R, Haywood P, Janlov N, Knight H, Lorenzoni L, Marino A, Or Z, Penneau A, Shatrov K, Stafford M, van de Galien O, van Gool K, Wodchis W, Jha AK. Differences in health care spending and utilization among older frail adults in high-income countries: ICCONIC hip fracture persona. <i>Health Serv Res</i> 2021;56(S3):1335–46. https://doi.org/10.1111/1475-6773.13739 .	
Papanicolas I, Riley K, Abiona O, Arvin M, Atsma F, Bernal-Delgado E, Bowden N, Blankart CR , Deeny S, Estupiñán-Romero F, Gauld R, Haywood P, Janlov N, Knight H, Lorenzoni L, Marino A, Or Z, Penneau A, Schoenfeld AJ, Shatrov K, Stafford M, van de Galien O, van Gool K, Wodchis W, Jha AK, Figueroa JF. Differences in health outcomes for high-need high-cost patients across high-income countries. <i>Health Serv Res</i> 2021;56(S3):1347–57. https://doi.org/10.1111/1475-6773.13735 .	
Wodchis WP, Or Z, Blankart CR , Atsma F, Janlov N, Bai YQ, Penneau A, Arvin M, Knight H, Riley K, Figueroa JF, Papanicolas I. An international comparison of long-term care trajectories and spending following hip fracture. <i>Health Serv Res</i> 2021;56(S3):1383–93. https://doi.org/10.1111/1475-6773.13864 .	
Figueroa JF, Papanicolas I, Riley K, Abiona O, Arvin M, Atsma F, Bernal-Delgado E, Bowden N, Blankart CR , Deeny S, Estupiñán-Romero F, Gauld R, Haywood P, Janlov N, Knight H, Lorenzoni L, Marino A, Or Z, Penneau A, Shatrov K, van de Galien O, van Gool K, Wodchis W, Jha AK. International comparison of health spending and utilization among people with complex multimorbidity. <i>Health Serv Res</i> 2021;56(S3):1317–34. https://doi.org/10.1111/1475-6773.13708 .	
Blankart CR , Dams F, Penton H, Kaló Z, Zemplényi A, Shatrov K, Iskandar R, Federici C. Regulatory and HTA early dialogues in medical devices. <i>Health Policy</i> 2021;125(10):1322–9. https://doi.org/10.1016/j.healthpol.2021.07.010 .	
Shatrov K, Pessina C, Huber K, Thomet B, Gutzeit A, Blankart CR . Improving health care from the bottom up: Factors for the successful implementation of kaizen in acute care hospitals. <i>PLOS ONE</i> 2021;16(9):e0257412. https://doi.org/10.1371/journal.pone.0257412 .	
Pongiglione B, Torbica A, Blommestein H, Groot S de, Ciani O, Walker S, Dams F, Blankart R , Mollenkamp M, Kovács S, Tarricone R, Drummond M. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. <i>Int J Technol Assess Health Care</i> 2021;37(1):e62. https://doi.org/10.1017/S0266462321000301 .	
Rabbe S, Blankart CR , Franz W-M, Hager L, Schreyögg J. Impact of a telemonitoring intervention in patients with chronic heart failure in Germany: A difference-in-difference matching approach using real-world data. <i>Journal of Telemedicine and Telecare</i> 2021;1357633X20984024. https://doi.org/10.1177/1357633X20984024 . https://doi.org/10.1177/1357633X20984024 .	

- Daubner-Bendes R, Kovács S, Niewada M, Huic M, Drummond M, Ciani O, **Blankart CR**, Mandrik O, Torbica A, Yfantopoulos J, Petrova G, Holownia-Voloskova M, Taylor RS, Al M, Piniazhko O, Lorenzovici L, Tarricone R, Zemplényi A, Kaló Z. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Frontiers in public health* 2021;8.
- Kodolitsch Y von, Prokoph M, Sachweh A, Kölbel T, Detter C, Berger J, Wick T, Debus S, **Blankart CR**. How military history can inspire medical intervention. *Cardiovascular diagnosis and therapy* 2020;10(6):2048–53. <https://doi.org/10.21037/cdt.2020.03.06>.
- Winter V, Kjærgaard Thomsen M, Schreyögg J, Blankart K, Duminy L, Schoenenberger L, Ansah JP, Matchar D, **Blankart CRB**, Oppel E. Improving Service Provision—The Health Care Services' Perspective. *Journal of service management research* 2019;3(4):163–83.
- Blankart CR**, Foster AD, Mor V. The effect of political control on financial performance, structure, and outcomes of US nursing homes. *Health Serv Res* 2019;54(1):167–80. <https://doi.org/10.1111/1475-6773.13061>.
- Varabyova Y, **Blankart CR**, Schreyögg J. Erratum to: Using nonparametric conditional approach to integrate quality into efficiency analysis: empirical evidence from cardiology departments. *Health Care Manag Sci* 2017;20(4):577.
- Varabyova Y, **Blankart CR**, Schreyögg J. Using nonparametric conditional approach to integrate quality into efficiency analysis: empirical evidence from cardiology departments. *Health Care Manag Sci* 2017;20(4):565–76.
- Blankart CR**, Stargardt T. Preferred supplier contracts in post-patent prescription drug markets. *Health Care Manag Sci* 2017;20(3):419–32.
- Varabyova Y, **Blankart CR**, Torbica A, Schreyögg J. Comparing the efficiency of hospitals in Italy and Germany: Nonparametric conditional approach based on partial frontier. *Health Care Manag Sci* 2017;20(3):379–94.
- Hatz MHM, Sonnenschein T, **Blankart CR**. The PMA scale: a measure of physicians' motivation to adopt medical devices. *Value in Health* 2017;20(4):533–41.
- Varabyova Y, **Blankart CR**, Greer AL, Schreyögg J. The determinants of medical technology adoption in different decisional systems: A systematic literature review. *Health Policy* 2017;121(3):230–42.
- Fuchs S, Olberg B, Panteli D, Perleth M, Busse R, Varabyova Y, **Blankart CR**, Greer AL, Schreyögg J, Lee HJ. Evaluating and adopting medical devices-challenges, determinants and preferences 2017.
- Hatz MHM, Schreyögg J, Torbica A, Boriani G, **Blankart CRB**. Adoption decisions for medical devices in the field of cardiology: results from a European survey. *Health Econ* 2017;26:124–44.
- Varabyova Y, **Blankart CR**, Schreyögg J. The role of learning in health technology assessments: an empirical assessment of endovascular aneurysm repairs in German Hospitals. *Health Econ* 2017;26:93–108.
- Schlage V, **Blankart CR**. Does direct-care staffing impact nursing home outcomes? A systematic review. *Die Unternehmung* 2016;70(3):291–318.
- Blankart CR**, Milstein R, Rybczynski M, Schüler H, Kodolitsch Y von. Economic and care considerations of Marfan syndrome. *Expert Rev Pharmacoecon Outcomes Res* 2016;16(5):591–8.
- Sachweh A, Kodolitsch Y von, Kölbel T, Larena-Avellaneda A, Wipper S, Am Bernhardt, Girdauskas E, Detter C, Reichenspurner H, **Blankart CR**. I-SWOT als Instrument zur individuell optimierten Therapie bei thorakoabdominalem Aortenaneurysma. *Gefässchirurgie* 2016;21(5):307–16.
- Blankart CR**, Emanuel EJ, Bekelman JE. Characteristics of Patients Dying With Cancer in Developed Countries—Reply. *JAMA* 2016;315(24):2732.
- Frey S, **Blankart CR**, Stargardt T. Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature. *Pharmacoeconomics* 2016;34(5):479–98.
- Milstein R, **Blankart CR**. The health care strengthening act: the next level of integrated care in Germany. *Health Policy* 2016;120(5):445–51.
- Bekelman JE, Halpern SD, **Blankart CR**, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-Philipsen B. International Consortium for End-of-Life Research (ICELR). Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. *JAMA* 2016;315(3):272–83.
- Kodolitsch Y von, **Blankart CR**, Vogler M, Kallenbach K, Robinson PN. Genetik und Prävention am Beispiel genetischer Aortensyndrome (GAS) und des Marfan-Syndroms. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2015;58(2):146–53.
- Ciani O, Wilcher B, **Blankart CR**, Hatz M, Rupel VP, Erker RS, Varabyova Y, Taylor RS. Health technology assessment of medical devices: a survey of non-European union agencies. *Int J Technol Assess Health Care* 2015;31(3):154–65.
- Achelrod D, **Blankart CR**, Linder R, Kodolitsch Y von, Stargardt T. The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. *Orphanet J Rare Dis* 2014;9(1):1–12.
- Blankart CR**, Koch T, Linder R, Verheyen F, Schreyögg J, Stargardt T. Cost of illness and economic burden of chronic lymphocytic leukemia. *Orphanet J Rare Dis* 2013;8(1):1–9.
- Blankart CR**. Does healthcare infrastructure have an impact on delay in diagnosis and survival? *Health Policy* 2012;105(2–3):128–37.
- Blankart CR**, Stargardt T, Schreyögg J. Availability of and access to orphan drugs. *Pharmacoeconomics* 2011;29(1):63–82.
- Blankart R**, Schreyögg J, Busse R. Performance of reimbursement schemes in valuation of technologies: The example of Magnetic Resonance Imaging. *Technol Health Care* 2008;16(3):171–82.
- Blankart R**, Blankart CB. Der Spendenmultiplikator. *WiSt-Wirtschaftswissenschaftliches Studium* 2002;31(8):465–6.